So it gives a probability of high grade cancer today, which goes into the decision making for biopsy. The test also gives a probability of developing a high grade cancer 5, 10, 15, and 20 years down the road. This can be comforting to those with a very low probability, but also comforting to those who know they are clear today, but need to be monitored more closely if they have a higher future risk. This aspect has never really been mentioned, but it is on the most recent Jefferies slides. There is a genetic test that can do this too, but it requires biopsy tissues, not just a blood sample.
My thinking is uptake of this test will be slow but steady, getting in the guidelines, or endorsement from ACS, or Boxer-Sessions committee will go a long way toward getting this test more main stream. Lowering the cost per test to around 60, and marketing it as a new improved psa could be the ticket. That of course is a Dr. Frost call, and one he might make in time.
in December. Thought it would get nearer 28 mpg, combined, that might have been a real edge.
Stiefels pt is lower than consensus at 6.00, The Thomson/First Call consensus is higher at $7. Shares closed Wednesday at $3.53. Hitting the Stifel target would be a monster 65% gain. Top line data from Astra should do the trick, and announcing NDA, return of B from Novartis could get arry to the First call target of 7.00, both events are under 6 months, accumulate now.
The 625 refers to current global employees in US, Canada, Mexico, Ireland, Spain, Brasil, Chile, etc. curious but betting we have more employees globally than in the states. I left out Russia, technically they are not our employees, but employees of a company we are invested in. If we include all investments it is well over 3000 people but opko pays for a small % of of the staff Frost has researching break through technology.
the revenue, eps etc is coming, faster than some think.
Author was Todd Cambell.
Phillip Frost gets my nod as the most influential CEO in biotech. Frost is the visionary behind Ivax, a generic drugmaker that was sold to Teva Pharmaceutical (NYSE: TEVA ) for $7 billion in 2006.
That sale not only catapulted Frost onto the short list of billionaire biotech leaders, but eventually seated him firmly in the top spot as Chairman of the Board at Teva, one of the globe’s biggest drug companies. Frost’s success at Ivax and later at Teva (including his hand in selecting the management team and providing strategic guidance that led to a doubling of the company’s revenue since 2008) places him among one of the few biotech guru’s that investors should be tracking. That is especially true since Frost remains a prolific entrepreneur.
In addition to his role at Teva, Frost is the CEO of Opko Health (NYSE: OPK ) , a development-stage company working on a slate of drugs and diagnostic tests. Frost’s past success and private-equity chops, including a string of acquisitions at Opko, make him worth watching in this fast-moving industry.
Hamster wheel, lol, yes. Holidays coming, they are posting like crazy to get cash for that new water bottle.
not likely losing all, but depends on their entry point, but that said, BROKERAGE firms do not NEED borrow retail shares on most stocks. This item, opk, IS a small float stock which creates availability issues. Remember half the float is insider owned and cannot be lent out. Of non insiders retail owns HALF, they need retail shares because the real float is small, getting smaller as I type. Though some might think retail holds little, well there are ONLY 400 share holders in this stock IF 50-60 are lending their shares, it is a bigger number than some think. Though some might think, well. I am not having trouble finding shares to short, well, there is a good chance that is because retail is lending 10-15m shares makes that possible. If 5-6 million shares 15-20 of the bigger holders opt out of the program, the availability vanishes in under a week.
Ask your self this, why did they raise the interest rate on borrowed shares from 6-10%, the answer is availability had vanished.
think it rallies year end, but down almost every day this month, gild too.
So 8 pages back, rough audience.
do you think it drops back into the 90's.
ARRY) is a top small cap to buy at Stifel. The company focuses on the discovery, development and commercialization of small molecule drugs to treat patients with cancer and inflammatory diseases, primarily in North America, Europe and the Asia-Pacific. The company’s MEK inhibitors, binimetinib and selumetinib, are currently advancing in six Phase 3 trials, and Array’s partners expect the firm’s first regulatory filing next year with top line results from the other trials available in 2016. In addition, it continues to collect data on the wholly owned filanesib program in two Phase 2 multiple myeloma trials, including a randomized combination trial with Kyprolis. With the progress, the company expects potential commercial revenues within the next two years.
The second they asked you to enter the program, that day, shorts ran out of ammo. The logic I hear is, WELL the funds lend their shares, so mine mean little. WRONG, not ALL funds lend, if they are going to BEG retail for shares to short, guess what, the funds that would lend did, the rest said, beat it. All the fund shares that might be used to SHORT were GONE.
Opko HAS more shares in retail hands than in the hands of funds, but there are ENOUGH fund shares if they were ALL Lent out they would not NEED YOURS. Fact is the SHORTS do need yours, many funds protect their toes by NOT lending.
So here is how retail shoots off their toes. They start lending their non margin shares for a fat yield even though many funds will not. So shorts who had a six shooter now have a gatling gun thanks to the new life provided by longs. They use these shares to tap the shares, hitting stops, creating a down trend.
So at a point the long who is lending his shares, though funds aren't lending enough, starts getting nervous, and thanks to their loan, they eventually buy high, sell low as they exit the program selling at market, again helping the shorts. They were NET short ANYWAY, but hopefully the next owner understands the dynamics.
When you have a small float stock and the broker BEGS you to take a 10% payment so you can shoot yourself, just sell the shares, you are net short anyway, or tell them get lost.
Now if you all lend your shares and think an insider can buy enough to stop this, rough job, when his share holders are handing bullets to the other side, a lot of bullets. The brokers were begging for shares and
LONGS ? rushed to lend them when OPKO was in the 10.40 range. So if you are in the program, accumulate, as a net short, you got your wish, the price is lower, you got your 10%, but lost about 18% in portfolio value. If you panic sell, your 10% yield is an 8% loss.
Agree with hellbent, a controlled take down. There is some short covering going on if you notice at IAB, availability rises all day. So they tap it down by shorting enough to get it moving then wait for retail to sell as they cover.
Idiot longs lending their shares out is part of the problem. If 5-6M removed their shares from the program there would be no shares to tap with. Fund ownership has grown every Q this year.
This is my best guess, I have no crystal ball, but it is a contrived sell off on no news. In fact the news has been positive for the most part. There has been no real heavy buying or selling pressure, but controlled pressure to cover part of an over crowded short trade. Earnings it was off a few cents so that is not the issue.
So short term, or glancing at the portfolio every half hour it is not fun. Longer term, Rolapitant and Rayaldee come to market, 4 blood tests. They will generate way MORE than Lakewood thought, but they are singles, not grand slams. Though Rayaldee could surprise all of us.
Teva has Major operations in Japan, a comarketing deal for Rayaldee with Teva could be an interesting event. There will be a marketing deal sooner than later, not sure on partner, Teva makes sense though.
want to look at facts instead of this trash. So many desperate individuals taking a robo job.
5 phase 3 drugs listed but fact is two of the phase 3 are finished, NDA for Rolapitant is out, Rayaldee in a couple weeks. 4 blood tests listed one active, 4k launch in Mexico is NOW scheduled for this year, 2014, was q1 2015. Psa filing q3, testosterone filing Q2, No filing date for D, likely Q3, but could be Q4.
4 phase 3 drugs, etc.,